ClinicalTrials.gg
Not yet recruitingNCT07565441Updated May 4, 2026

Drug-Drug Interactions of JMKX003142 in Healthy Participants

A Phase 1 interventional study of JMKX003142 tablets and Fluconazole Capsules in ADPKD (Autosomal Dominant Polycystic Kidney Disease), sponsored by Jemincare. Not yet recruiting. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Jemincare · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a single-center, non-randomized, open-label, self-controlled, Phase I clinical trial to evaluate the drug-drug interactions (DDI) of JMKX003142 tablets in healthy adult participants.

The study consists of five cohorts (Cohorts 1, 2, 3, 4, and 5). A total of 24 participants are planned enrollment in each of Cohorts 1, 2, 3, and 5, while 16 participants are planned for Cohort 4.

02

Conditions studied

  • ADPKD (Autosomal Dominant Polycystic Kidney Disease)
03

In context

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

This study's planned enrollment of 112 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.

Browse Polycystic Kidney, Autosomal Dominant studies →

Lead sponsor

Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants are able to return to the study center for follow-up as required by the protocol and are willing to comply with study policies, procedures, and restrictions; capable of effective communication with the investigator and completing study-related materials; able to understand the contents of the Form (ICF) and sign the written ICF prior to any study procedures.
  2. Healthy Chinese male or female subjects, as determined by medical history and physical examination. At the time of signing the Informed Consent Form (ICF), aged 18-45 years (inclusive) ; body weight ≥ 50 kg for males or ≥ 45 kg for females; and (BMI) within the range of 19.0-26.0 kg/m² (inclusive).
  3. Participants were considered healthy by the Investigator based on medical history, baseline physical examination, clinical laboratory assessments, and 12-lead , with all results judged as normal or not .
  4. Participants of who agree to use effective and have no plans for conception, cryopreservation, or donation of gametes from ICF signature through 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected to JMKX003142 (active ingredient or ), or a history of hypersensitivity to more than two drugs, foods, or other substances.
  2. History or presence of diseases in any of the following systems (including but not limited to): cardiovascular, respiratory, gastrointestinal, hematologic, genitourinary, endocrine/metabolic, nervous, psychiatric, musculoskeletal, dermatologic, lymphatic, immune, or sensory organs; or current active local or systemic infection.
  3. Any condition increasing the risk of bleeding, such as acute gastritis, active ulcer with hemorrhage, clinically significant thrombocytopenia or anemia, active pathological bleeding, or a history of intracranial hemorrhage.
  4. Vital signs meet any of the following criteria at screening: systolic blood pressure ≥ 140 mmHg or \< 90 mmHg; diastolic blood pressure ≥ 90 mmHg or \< 50 mmHg; pulse rate > 100 bpm or \< 50 bpm; or tympanic temperature ≥ 37.5°C or \< 35°C.
  5. Subjects with a history of prolongation or a family history of Long QT Syndrome; or those with clinically significant abnormal findings as determined by the Investigator during screening; or a QTcF ≥ 450 ms; or a QRS interval > 120 ms.
  6. Positive for surface antigen (HBsAg), virus (HCV) antibody, (HIV) antibody, or syphilis serology.
  7. Treatment with therapeutic biological products within 3 months (or 5 half-lives, whichever is longer) prior to dosing, or other prescription/non-prescription medications (including vaccines, Traditional Chinese Medicine [TCM], dietary supplements, and health products) within 1 month (or 5 half-lives, whichever is longer).
  8. Use of any drug within 3 months prior to screening, or current participation in another clinical trial.
  9. Major surgery (e.g., requiring general or epidural anesthesia) within 3 months prior to screening, or planned surgical intervention during the study.
  10. History of hemophobia, belonephobia, or difficult venous access.
  11. Blood donation or blood loss of ≥400 mL within 3 months prior to screening.
  12. History of drug dependence/abuse or illicit drug use, or a positive drug screening result.
  13. Smoking ≥5 cigarettes per day within 3 months prior to screening, or inability to commit to abstaining from tobacco products during the study, or a positive nicotine screening result.
  14. History of heavy alcohol consumption (>14 units per week; 1 unit ≈ 10 mL alcohol, equivalent to approx. 285 mL beer [3.5%], 25 mL spirits [40%], or 100 mL wine [10%]), inability to abstain from alcohol after screening, or a positive alcohol breath test.
  15. Daily consumption of excessive tea, coffee, or caffeine-containing beverages (more than 8 cups per day; 1 cup = 250 mL) within 14 days prior to screening.
  16. Ingestion of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos) or fruit products within 3 days prior to dosing.
  17. Special dietary requirements, or inability to comply with a standardized diet (e.g., standard meals) and dietary restrictions.
  18. Pregnancy or lactation, positive pregnancy test in females, unprotected sexual intercourse with a partner within 14 days prior to screening, use of oral within 30 days prior to screening, or use of long-acting injectable or implanted estrogens/progestogens within 6 months prior to screening.
  19. Requirement to drive long distances, work at heights, or operate complex machinery during the study.
  20. Other conditions that, in the investigator's opinion, would make the subject unsuitable for participation in this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Cohort 1: To evaluate the effect of fluconazole on the pharmacokinetic (PK) profile of JMKX003142

    Drug: JMKX003142 tablets · Drug: Fluconazole Capsules

  • Experimental
    Cohort 2: To evaluate the effect of JMKX003142 on the PK profiles of Cocktail Substrates

    Drug: Cocktail Substrates (Midazolam Oral Solution, Rosuvastatin Calcium Tablets, and Digoxin Tablets) · Drug: JMKX003142 tablets

  • Experimental
    Cohort 3: To evaluate the effect of cyclosporine on the pharmacokinetic (PK) profile of JMKX003142

    Drug: JMKX003142 tablets · Drug: Cyclosporine Soft Capsules

  • Experimental
    Cohort 4: To evaluate the effect of omeprazole on the pharmacokinetic (PK) profile of JMKX003142

    Drug: Omeprazole Enteric-coated Tablets · Drug: JMKX003142 tablets

  • Experimental
    Cohort 5: To evaluate the effect of efavirenz on the pharmacokinetic (PK) profile of JMKX003142

    Drug: Efavirenz Tablets · Drug: JMKX003142 tablets

Interventions

  • 3mg once daily (QD) on Day 1 and Day 7

  • DrugFluconazole Capsules

    400mg QD on Day 4, 200mg QD from Day 5 to Day 9

  • DrugCocktail Substrates (Midazolam Oral Solution, Rosuvastatin Calcium Tablets, and Digoxin Tablets)

    Midazolam Oral Solution 2mg, Rosuvastatin Calcium Tablets 5mg and Digoxin Tablets 0.25mg QD on Day 1, Day 8 and Day 21

  • DrugCyclosporine Soft Capsules

    100 mg twice daily (BID) from Day 4 to Day 9

  • DrugOmeprazole Enteric-coated Tablets

    40mg QD from Day 4 to Day 8

  • DrugEfavirenz Tablets

    600mg QD from Day 4 to Day 12

  • 6mg QD from Day 8 to Day 25

  • 6mg QD on Day 1 and Day 8

  • 6mg QD on Day 1 and Day 10

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of JMKX003142 and its metabolites

    Time frame: for 120 hours

  2. Area Under Curve (AUC) of JMKX003142 and its metabolites

    Time frame: for 120 hours

  3. Maximum Plasma Concentration (Cmax) of Midazolam and its metabolites

    Time frame: for 144 hours

  4. Area Under Curve (AUC) of of Midazolam and its metabolites

    Time frame: for 144 hours

  5. Maximum Plasma Concentration (Cmax) of Rosuvastatin

    Time frame: 144 hours

  6. Area Under Curve (AUC) of of Rosuvastatin

    Time frame: for 144 hours

  7. Maximum Plasma Concentration (Cmax) of Digoxin

    Time frame: for 144 hours

  8. Area Under Curve (AUC) of Digoxin

    Time frame: for 144 hours

Secondary outcomes

  1. Tmax of JMKX003142 and its metabolites

    Time frame: for 120 hours

  2. T1/2 of JMKX003142 and its metabolites

    Time frame: for 120 hours

  3. CL of JMKX003142 and its metabolites

    Time frame: for 120 hours

  4. Tmax of Midazolam and its metabolites

    Time frame: for 144 hours

  5. T1/2 of Midazolam and its metabolites

    Time frame: for 144 hours

  6. CL of Midazolam and its metabolites

    Time frame: for 144 hours

  7. Tmax of Rosuvastatin

    Time frame: for 144 hours

  8. T1/2 of Rosuvastatin

    Time frame: for 144 hours

  9. CL of Rosuvastatin

    Time frame: for 144 hours

  10. Tmax of Digoxin

    Time frame: for 144 hours

  11. T1/2 of Digoxin

    Time frame: for 144 hours

  12. CL of Digoxin

    Time frame: for 144 hours

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Nov 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 4, 2026
StartEst.
May 11, 2026
Primary completionEst.
Nov 15, 2026
CompletionEst.
Feb 28, 2027
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07565441
Lead sponsor
Jemincare
Collaborators
Zhejiang Hangyu Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
May 4, 2026
Start date
May 11, 2026 (estimated)
Primary completion
Nov 15, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
May 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JMKX003142

Start the discussion